1. Search Result
Search Result
Pathways Recommended: Metabolic Enzyme/Protease
Results for "

metabolic disorders

" in MedChemExpress (MCE) Product Catalog:

146

Inhibitors & Agonists

5

Screening Libraries

1

Fluorescent Dye

3

Biochemical Assay Reagents

2

Peptides

28

Natural
Products

9

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-153759

    PPAR Metabolic Disease
    CRX000227 is a PPAR modulator. CRX000227 can be used for research of metabolic or cell proliferative disorders .
    CRX000227
  • HY-U00461

    Ketohexokinase inhibitor 1

    Ketohexokinase Metabolic Disease
    PF-06835919 (Ketohexokinase inhibitor 1) is an inhibitor of ketohexokinase (KHK), with IC50s of 8.4 nM and 66 nM for KHK-C and KHK-A, respectively. PF-06835919 can be used for the study of metabolic disorders driven by the overconsumption of Fructose (HY-N0395) .
    PF-06835919
  • HY-110178

    MAGL Inflammation/Immunology
    WWL123, a carbamate-based compound, is a potent and selective ABHD6 inhibitor. WWL123 can be used for research of inflammation, metabolic disorders (obesity and type II diabetes mellitus) and epilepsy .
    WWL123
  • HY-W012734
    L-Pipecolic acid
    1 Publications Verification

    H-HoPro-OH

    Endogenous Metabolite Metabolic Disease
    L-Pipecolic acid (H-HoPro-OH) is an oral active metabolite of Lysine and can accumulate in the bodily fluids of infants with autosomal inherited diseases, such as Zellweger syndrome and neonatal adrenal insufficiency. L-Pipecolic acid can promote muscle cell health and growth by enhancing protein synthesis, and plays a role in promoting gut health. L-Pipecolic acid holds promise for research in the fields of metabolic disorders, muscle growth disorders, and intestinal diseases .
    L-Pipecolic acid
  • HY-156527

    HIF/HIF Prolyl-Hydroxylase Cancer
    PHD-IN-2 (Compound 91) is a PHD antagonist (IC50: < 5 nM). PHD-IN-2 induces erythropoietin synthesis in HEP3B cells (EC50: <2.5 μM). PHD-IN-2 can be used for research of cardiovascular disorders, metabolic disorders, hematological disorders, pulmonary disorders, kidney disorders, liver disorders, wound healing disorders, and cancer .
    PHD-IN-2
  • HY-19425

    PPAR Metabolic Disease
    NS-220 is an orally active PPARα agonist with high subtype selectivity, with EC50 values of 1.9×10 -8 M, 9.6×10 -6 M and >10 -4 M for PPARα, PPAR γ and PPARδ, respectively. NS-220 is used in the research for hyperlipidemia or metabolic disorders in type-2 diabetes .
    NS-220
  • HY-147049

    Epoxide Hydrolase Metabolic Disease
    PAL-4 (compound 4) is a potent, selective and reversible Lysophospholipase-like 1 (LYPLAL1) activator with EC50 value of 0.39 μM and 0.49 μM for mice LYPLAL1 and huamn LYPLAL1, respectively. PAL-4 can be used for researching metabolic disorders .
    PAL-4
  • HY-W109401

    Sirtuin Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    SIRT-IN-6 (Compound 14) is a pan-inhibitor of SIRT1/2/3 with IC50 values of >50 μM. SIRT-IN-6 is promising for research of metabolic, inflammatory, oncologic and neurodegenerative disorders .
    SIRT-IN-6
  • HY-160168

    Btk Infection Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology Endocrinology Cancer
    BTK-IN-31 (Compound 2) is a selective, non-covalently reversible, and blood-brain barrier (BBB) permeable Btk inhibitor. BTK-IN-31 has research potential in immune disorders, cancer, cardiovascular disease, viral infections, inflammation, metabolic/endocrine dysfunction, and neurological disorders .
    BTK-IN-31
  • HY-126907

    Dopamine β-hydroxylase Bacterial Infection Cardiovascular Disease Metabolic Disease
    A32390A is a dopamine β-hydroxylase inhibitor and copper chelator. A32390A can inhibit the synthesis of norepinephrine, which helps lower blood pressure in DOCA hypertensive rats. A32390A can be used in research on hypertension, bacterial infections, and metabolic disorders .
    A32390A
  • HY-133556

    AMPK Metabolic Disease
    IQZ23 inhibits adipocyte differentiation via AMPK pathway activation. IQZ23 exerts a high efficacy in decreasing the triglyceride level (EC50=0.033 μM) in 3T3-L1 adipocytes. IQZ23 could be used for the research of obesity and related metabolic disorders .
    IQZ23
  • HY-W012734R

    Endogenous Metabolite Metabolic Disease
    L-Pipecolic acid (Standard) is an analytical standard of L-Pipecolic acid. This product is used for research and analytical applications. L-Pipecolic acid (H-HoPro-OH) is an oral active metabolite of Lysine and can accumulate in the bodily fluids of infants with autosomal inherited diseases, such as Zellweger syndrome and neonatal adrenal insufficiency. L-Pipecolic acid can promote muscle cell health and growth by enhancing protein synthesis, and plays a role in promoting gut health. L-Pipecolic acid holds promise for research in the fields of metabolic disorders, muscle growth disorders, and intestinal diseases .
    L-Pipecolic acid (Standard)
  • HY-158130

    FKBP HSP Neurological Disease Metabolic Disease Cancer
    FKBP51-Hsp90-IN-1 (Compound D10) is a selective inhibitor of the FKBP51-Hsp90 protein-protein interaction, with an IC50 value of 0.1 μM against FKBP51. FKBP51-Hsp90-IN-1 can be used in the research of stress-related diseases, Alzheimer's disease, and metabolic disorders .
    FKBP51-Hsp90-IN-1
  • HY-117516

    REV-ERB Neurological Disease Metabolic Disease
    SR10067 is a potent, selective and brain penetrant REV-ERB agonist. SR10067 has high affinity for Rev-Erbβ and Rev-Erbα with IC50 values of 160 nM and 170 nM, respectively. SR10067 can be used for the research of metabolic diseases and neuropsychiatric disorders .
    SR10067
  • HY-153476

    GCGR Metabolic Disease
    GIP/GLP-1 dual receptor agonist-1 (compound 4) is a GIP/GLP-1 receptor agonist. GIP/GLP-1 dual receptor agonist-1 can be used in the research of metabolic disorders and fatty liver diseases, including nonalcoholic steatohepatitis (NASH) and nonalcoholic fatty liver disease (NAFLD) .
    GIP/GLP-1 dual receptor agonist-1
  • HY-103462

    FAAH Cardiovascular Disease Metabolic Disease Inflammation/Immunology Cancer
    TC-F2 is a reversible non-covalent binding inhibitor of fatty acid amide hydrolase (FAAH) with an IC50 of 28 nM. FAAH is involved in many human diseases, particularly cancer, pain and inflammation as well as neurological, metabolic and cardiovascular disorders .
    TC-F2
  • HY-146731

    PPAR Cardiovascular Disease Metabolic Disease
    PPARγ agonist 1 (compound 15) is a potent agonist of PPARγ. PPARγ agonist 1 shows high efficacy to activate hPPARγ without raising a full agonism and probably avoiding adverse effects. PPARγ agonist 1 has the potential for the research of cardiovascular diseases associated with metabolic disorders .
    PPARγ agonist 1
  • HY-N8466

    Reactive Oxygen Species Metabolic Disease
    (-)-Lyoniresinol 9'-O-glucoside is an inhibitor of ROS. (-)-Lyoniresinol 9'-O-glucoside reduces lipid accumulation and lipid metabolic disorders in FFAs-exposed HepG2 cells. (-)-Lyoniresinol 9'-O-glucoside inhibits high glucose-induced reactive oxygen species production .
    (-)-Lyoniresinol 9'-O-glucoside
  • HY-132205

    Estrogen Receptor/ERR Metabolic Disease
    DS45500853 is an estrogen-related receptor α (ERRα) agonist. DS45500853 inhibits the binding between receptor-interacting protein 140 (RIP140) corepressor peptide (10 nM) and GST-ERRα ligand-binding domain (LBD; 1.2 μM) with an IC50 value of 0.80 μM. DS45500853 can be used for the research of metabolic disorders, including type 2 diabetes mellitus (T2DM) .
    DS45500853
  • HY-14280
    Entacapone
    5 Publications Verification

    COMT Neurological Disease Cancer
    Entacapone is a potent, reversible, peripherally acting and orally active catechol-O-methyltransferase (COMT) inhibitor. Entacapone inhibits COMT from rat brain, erythrocytes and liver with IC50 values of 10 nM, 20 nM, and 160 nM, respectively. Entacapone is selective for COMT over other catecholamine metabolizing enzymes, including MAO-A, MAO-B, phenolsulphotransferase M (PST-M) and PST-P (IC50s>50 µM). Entacapone can be used for the research of Parkinson's disease . Entacapone serves as a inhibitor of FTO demethylation with an IC50 of 3.5 μM, can be used for the research of metabolic disorders .
    Entacapone
  • HY-162928

    RIP kinase Neurological Disease
    RIPK1-IN-26 (Compound 8a) is a potent receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor with cell anti-necroptosis potency. RIPK1-IN-26 demonstrats good metabolic stability and good binding specificity in mice. RIPK1-IN-26 is promising for research of PET imaging probe development and neurodegenerative disorders .
    RIPK1-IN-26
  • HY-144827

    Cannabinoid Receptor Neurological Disease Metabolic Disease
    AM8936 acts as a balanced and potent cannabinoid receptor type-1 (CB1) agonist in functional assays (EC50s of 8.6 and 1.4 nM for rCB1 and hCB1, respectively). AM8936 exhibits high affinity for rat CB1 (rCB1) with Ki of 0.55 nM. AM8936 is a potent and efficacious CB1 agonist in vivo. AM8936 can be used for the research of CNS and metabolic disorders, pain, glaucoma, etc .
    AM8936
  • HY-149663

    Acyltransferase Metabolic Disease
    BMS-986172 is an orally active, highly selective MGAT2 inhibitor with an IC50 of 4.6 nM and 20 nM for hMGAT2 and mMGAT2, respectively. BMS-986172 has a T1/2>120 min in vitro assays. BMS-986172 reduces food intake and body weight. BMS-986172 has the potential for metabolic disorders such as obesity and NASH research .
    BMS-986172
  • HY-14280A

    COMT Neurological Disease Cancer
    Entacapone sodium salt is a potent, reversible, peripherally acting and orally active catechol-O-methyltransferase (COMT) inhibitor. Entacapone sodium salt inhibits COMT from rat brain, erythrocytes and liver with IC50 values of 10 nM, 20 nM, and 160 nM, respectively. Entacapone sodium salt is selective for COMT over other catecholamine metabolizing enzymes, including MAO-A, MAO-B, phenolsulphotransferase M (PST-M) and PST-P (IC50s>50 μM). Entacapone sodium salt can be used for the research of Parkinson's disease . Entacapone sodium salt serves as as a inhibit of FTO demethylation with an IC50 of 3.5 μM, can be used for the research of metabolic disorders .
    Entacapone sodium salt
  • HY-B1268
    Docusate Sodium
    1 Publications Verification

    Dioctyl sulfosuccinate sodium salt

    HSV Others
    Docusate Sodium (Dioctyl sulfosuccinate sodium salt) is one of the main components in stool softeners. Docusate Sodium is a sulfated surfactant and may inactivate viral pathogens by disrupting viral envelopes and/or denaturing/disassociating proteins. Docusate Sodium is effective in vitro against wild type and drug-resistant strains of HSV type 1 and 2. Docusate Sodium is an obesogen. Docusate Sodium with developmental exposure leads to increased adult adiposity, inflammation, metabolic disorder and dyslipidemia in offspring fed a standard diet in mice .
    Docusate Sodium
  • HY-143201

    Estrogen Receptor/ERR Metabolic Disease
    DS20362725 is an estrogen-related receptor α (ERRα) agonist. DS20362725 inhibits the binding between receptor-interacting protein 140 (RIP140) corepressor peptide (10 nM) and GST-ERRα ligand-binding domain (LBD; 1.2 μM) with an IC50 value of 0.6 μM. DS20362725 can be used for the research of metabolic disorders, including type 2 diabetes mellitus (T2DM) .
    DS20362725
  • HY-B1268R

    HSV Others
    Docusate (Sodium) (Standard) is the analytical standard of Docusate (Sodium). This product is intended for research and analytical applications. Docusate Sodium (Dioctyl sulfosuccinate sodium salt) is one of the main components in stool softeners. Docusate Sodium is a sulfated surfactant and may inactivate viral pathogens by disrupting viral envelopes and/or denaturing/disassociating proteins. Docusate Sodium is effective in vitro against wild type and drug-resistant strains of HSV type 1 and 2. Docusate Sodium is an obesogen. Docusate Sodium with developmental exposure leads to increased adult adiposity, inflammation, metabolic disorder and dyslipidemia in offspring fed a standard diet in mice .
    Docusate (Sodium) (Standard)
  • HY-112828

    DAGL Neurological Disease Metabolic Disease Inflammation/Immunology
    LEI105 is a potent, highly selective and reversible dual diacylglycerol lipase (DAGL)-α/DAGL-β inhibitor. LEI105 reduces 2-arachidonoylglycerol levels in Neuro2A cells. LEI105 also reduces cannabinoid CB1-receptor-mediated short-term synaptic plasticity in a mouse hippocampal slice model. LEI105 is promising for research of diseases, such as obesity, related metabolic disorders and neuroinflammation .
    LEI105
  • HY-U00397

    Cannabinoid Receptor Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology
    CB1 antagonist 1 is an antagonist of CB1 receptor, used in the research of metabolic syndrome and obesity, neuroinflammatory disorders, cognitive disorders and psychosis, gastrointestinal disorders, and cardiovascular conditions.
    CB1 antagonist 1
  • HY-148104
    ACSS2-IN-2
    1 Publications Verification

    Acetyl-CoA synthetase Infection Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    ACSS2-IN-2 is an acyl-CoA synthetase short-chain family member 2 (ACSS2) inhibitor. ACSS2-IN-2 can inhibit ACSS2 activity with an IC50 value of 3.8 nM. ACSS2-IN-2 can be used for the research of several diseases, such as viral infection, metabolic disorders, neuropsychiatric diseases, inflammatory/autoimmune conditions and cancer .
    ACSS2-IN-2
  • HY-153530

    IPK Superfamily Neurological Disease Metabolic Disease
    LI-2242 is an inositol hexakisphosphate kinase (IP6K) inhibitor. LI-2242 has inhibition effect for IP6K1, IP6K2, IP6K3 and IPMK with IC50 values of 31 nM, 42 nM, 8.7 nM and 1944 nM, respectively. LI-2242 can be used for thew research of type II diabetes, obesity, metabolic complications, venous thrombosis, and psychiatric disorders .
    LI-2242
  • HY-N9275

    Others Metabolic Disease Inflammation/Immunology
    Isopicropodophyllin is a natural compound that can be used for metabolic or chronic inflammatory disorder research .
    Isopicropodophyllin
  • HY-147627

    GLP Receptor Metabolic Disease
    GLP-1R agonist 14 (Compound 14) is a GLP-1 receptor agonist with an EC50 of 0-20 nM against h-GLP-1 .
    GLP-1R agonist 14
  • HY-N5134R

    5'-GMP (Standard); 5'-guanosine monophosphate (Standard)

    Endogenous Metabolite
    5'-Guanylic acid (5'-GMP) is a nucleotide and can be used as a feeding stimulant for aqua feed production. 5'-Guanylic acid is able to decrease the levels of anxiety. 5'-Guanylic acid increases Docosahexaenoic acid (DHA) (HY-B2167) content in the liver cells. Cyclic 5'-Guanylic acid or its butyrated analogues induces DNA synthesis .
    5'-Guanylic acid (Standard)
  • HY-109167

    R-(+)-Amisulpride

    Dopamine Receptor Neurological Disease
    Aramisulpride is a dopamine D2 receptor and serotonin receptor antagonist used for the research of metabolic disorders .
    Aramisulpride
  • HY-107574

    Histone Methyltransferase AP-1 NF-κB PKA Metabolic Disease Inflammation/Immunology Cancer
    TC-E 5003 is a selective protein arginine methyltransferase 1 (PRMT1) inhibitor with an IC50 of 1.5 µM against hPRMT1. TC-E 5003 modulates the lipopolysaccharide (LPS) (HY-D1056)-induced AP-1 and NF-κB signaling pathways with anti-inflammatory properties. TC-E 5003 also upregulates the expression of Ucp1 and Fgf21, activates protein kinase A signaling and lipolysis in primary subcutaneous adipocytes from both mouse and humans. TC-E 5003 is promising for research of obesity and associated metabolic disorders, oxidative stress, inflammation and cancers .
    TC-E 5003
  • HY-111327

    Glycosidase Metabolic Disease
    Valibose is analpha-glucosidaseinhibitor, and ameliorates the metabolic disorder of glucose and lipids and the nephropathy in Streptozotocin (HY-13753)-induced diabetic rats .
    Valibose
  • HY-113126B

    Endogenous Metabolite Others
    (R)-3-Hydroxyisobutyric acid (sodium) serves as a biochemical hallmark for the metabolic disorder known as 3-hydroxyisobutyric aciduria, characterized by elevated urinary concentrations.
    (R)-3-Hydroxyisobutyric acid sodium
  • HY-153525

    FXR Metabolic Disease Inflammation/Immunology
    FXR agonist 5 (compound 1) is a FXR agonist. FXR agonist 5 can be used for research in diseases or disorders caused by metabolic inflammation .
    FXR agonist 5
  • HY-P10910

    GLP Receptor Metabolic Disease
    Vensemaglutide is the agonist for glucagon-like peptide 1 (GLP-1) receptor. Vensemaglutide can be used in research of diabetes or other metabolic disorders .
    Vensemaglutide
  • HY-132924

    Acyltransferase Metabolic Disease Inflammation/Immunology
    BMS-963272 is an orally active and selective MGAT2 inhibitor (IC50 = 7.1 nM), used for the study of metabolic disorders and inflammatory diseases .
    BMS-963272
  • HY-113288

    LDLR Metabolic Disease
    Campestanol is a phytosterol that can be found in plant food. Campestanol lowers serum cholesterol and low-density lipoprotein. Campestanol can be used for the research of metabolic disorders .
    Campestanol
  • HY-114392
    Gly-β-MCA
    10+ Cited Publications

    FXR Autophagy Metabolic Disease
    Gly-β-MCA, a bile acid, is a potent, sable, intestine-selective and oral bioactive farnesoid X receptor (FXR) inhibitor that may be a candidate for the treatment of metabolic disorders .
    Gly-β-MCA
  • HY-139175

    PPAR Others
    ZLY032 is a dual FFA1/PPARδ agonist with the activity of improving glucose and lipid metabolism, alleviating liver fibrosis, and potentially inhibiting metabolic disorders.
    ZLY032
  • HY-117918

    FXR Metabolic Disease Inflammation/Immunology
    ST-1892 (compound 14) is a highly potent FXR agonist (EC50=7.2 nM) that can be used to study diseases or disorders caused by metabolic inflammation .
    ST-1892
  • HY-101455
    CDN1163
    10+ Cited Publications

    Calcium Channel Metabolic Disease
    CDN1163 is an allosteric sarco/endoplasmic reticulum Ca 2+-ATPase (SERCA) activator that improves Ca 2+ homeostasis. CDN1163 attenuates diabetes and metabolic disorders .
    CDN1163
  • HY-12813

    Phosphodiesterase (PDE) Neurological Disease
    PDE10-IN-1 is a potent PDE10-IN-1 inhibitor extracted from Patent WO 2013192273 A1, for treating CNS and metabolic disorders.
    PDE10-IN-1
  • HY-113013

    β-Hydroxypyruvic acid; 3-Hydroxypyruvic acid

    Endogenous Metabolite Metabolic Disease
    Hydroxypyruvic acid (β-Hydroxypyruvic acid) is an intermediate in the metabolism of glycine, serine and threonine. Hydroxypyruvic acid is a substrate for serine-pyruvate aminotransferase and glyoxylate reductase/hydroxypyruvate reductase. Hydroxypyruvic acid is involved in the metabolic disorder which is the dimethylglycine dehydrogenase deficiency pathway.
    Hydroxypyruvic acid
  • HY-N15342

    Estrogen Receptor/ERR Metabolic Disease Endocrinology
    Tschimganidin is an ERα agonist with an IC50 of 1.4 μM. Found in plants of the Apiaceae family, Tschimganidin is a terpenoid compound with anti-obesity activity. It can be used for research in the field of endocrine and metabolic disorders .
    Tschimganidin
  • HY-154867

    DNA Methyltransferase Cancer
    DNMT2-IN-1 (compound 80) is a potent and selective DNMT2 (DNA methyltransferase 2) inhibitor with an IC50 value of 1.2 μM, and has the potential for mental and metabolic disorders or cancer research .
    DNMT2-IN-1

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: